#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	12732	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2025	623.3	1	SNP	n	C1184T	0	.	.	1184	1184	C	1411	1411	C	767	C	714	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23242	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3397	680.3	0	.	n	.	0	T695C	SNP	695	695	T	950	950	C	734	C	668	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23242	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3397	680.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2226	2226	C	726	C	677	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23242	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3397	680.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2300	2300	A	716	A	675	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23242	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3397	680.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2852	2852	C	749	C,T	701,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	23242	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3397	680.3	0	HET	.	.	.	A1638G	.	1638	1638	A	1893	1893	A	738	A,G	545,139	.	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1688	folP	855	855	100.0	folP.l15.c4.ctg.1	1402	119.3	1	SNP	p	R229S	1	.	.	685	687	AGC	950	952	AGC	170;171;170	A;G;C	158;157;156	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4388	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3529	124.1	1	SNP	p	S91F	1	.	.	271	273	TTC	630	632	TTC	173;174;176	T;T;C	162;162;160	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4388	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3529	124.1	1	SNP	p	D95G	1	.	.	283	285	GGC	642	644	GGC	171;168;167	G;G,A;C	154;152,1;149	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4388	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3529	124.1	1	SNP	p	G95N	0	.	.	283	285	GGC	642	644	GGC	171;168;167	G;G,A;C	154;152,1;149	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_O_01438	mtrR.WHO_O_01438	1	1	27	1316	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1372	95.8	1	SNP	p	G45D	0	.	.	133	135	GGC	514	516	GGC	161;159;159	G;G;C	152;148;149	mtrR.WHO_O_01438:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	648	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1028	62.7	0	.	n	.	0	A197.	DEL	197	197	A	560	560	A	148	A	138	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4812	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2943	162.7	1	SNP	p	D86N	0	.	.	256	258	GAC	571	573	GAC	220;224;223	G,T;A;C	199,1;201;204	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4812	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2943	162.7	1	SNP	p	R87W	0	.	.	259	261	CGT	574	576	CGT	220;215;214	C;G;T	201;196;195	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4812	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2943	162.7	1	SNP	p	R87I	0	.	.	259	261	CGT	574	576	CGT	220;215;214	C;G;T	201;196;195	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4812	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2943	162.7	1	SNP	p	S87R	1	.	.	259	261	CGT	574	576	CGT	220;215;214	C;G;T	201;196;195	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	4812	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2943	162.7	1	SNP	p	S88P	0	.	.	262	264	TCC	577	579	TCC	215;217;215	T,A;C;C	195,1;198;199	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3426	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2545	133.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1483	1485	GGC	159;159;158	G;G;C	147;145;144	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	3174	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2412	131.2	1	SNP	p	A311V	0	.	.	931	933	GCC	1279	1281	GCC	180;181;182	G;C;C	163;166;167	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3174	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2412	131.2	1	SNP	p	I312M	1	.	.	934	936	ATG	1282	1284	ATG	182;184;183	A;T;G	167;169;168	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3174	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2412	131.2	1	SNP	p	T316P	0	.	.	946	948	ACC	1294	1296	ACC	186;182;179	A;C;C	166;163;161	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3174	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2412	131.2	1	SNP	p	V316T	1	.	.	946	948	ACC	1294	1296	ACC	186;182;179	A;C;C	166;163;161	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3174	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2412	131.2	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1795	1797	ACC	187;187;189	A;C;C	163;165;169	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3174	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2412	131.2	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1849	1851	GCG	185;182;185	G;C;G	173;173;175	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3174	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2412	131.2	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1849	1851	GCG	185;182;185	G;C;G	173;173;175	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3174	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2412	131.2	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1972	1974	GGT	117;115;116	G;G;T	105;106;106	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3174	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2412	131.2	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1981	1983	AGC	110;110;110	A;G;C	102;103;101	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3174	penA	1746	1746	100.0	penA.l6.c4.ctg.1	2412	131.2	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1999	2001	CCG	98;97;93	C,G;C,G;G	76,6;76,1;70	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4838	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3084	156.4	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1617	1619	CCG	178;179;179	C,A;C;G	158,1;165;160	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2048	porA	1146	1146	99.91	porA.l15.c4.ctg.1	1708	119.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	517	517	C	158	C	145	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	A251V	NONSYN	751	753	GCG	78	80	GTA	28;29;29	G;T;A	24;24;24	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	S271T	NONSYN	811	813	TCG	138	140	ACT	36;31;31	A;C;T	32;28;28	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	Y273D	NONSYN	817	819	TAT	144	146	GAT	26;25;24	G;A;T	24;23;22	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	D276N	NONSYN	826	828	GAT	153	155	AAC	23;23;23	A;A;C	21;20;21	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	N277H	NONSYN	829	831	AAC	156	158	CAC	24;24;24	C;A;C	21;21;21	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	R307E	NONSYN	919	921	AGA	246	248	GAA	11;11;11	G;A;A	11;11;11	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	T311A	NONSYN	931	933	ACA	258	260	GCA	10;9;9	G;C;A	10;9;9	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	E312D	NONSYN	934	936	GAA	261	263	GAC	9;9;9	G;A;C	9;9;9	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	F314I	NONSYN	940	942	TTC	267	269	ATC	5;5;5	A;T;C	5;5;5	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	A316S	NONSYN	946	948	GCG	273	275	TCG	5;5;5	T;C;G	5;5;5	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	V318A	NONSYN	952	954	GTC	279	281	GCC	3;3;3	G;C;C	3;3;3	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	G319S	NONSYN	955	957	GGC	282	284	AGC	3;3;2	A;G;C	3;3;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	G320A	NONSYN	958	960	GGT	285	287	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	528	252	porB1a	984	271	91.51	porB1a.l6.c30.ctg.1	394	16.1	0	.	p	.	0	G322V	NONSYN	964	966	GGT	291	293	GTT	1;1;1	G;T;T	1;1;1	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2470	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1673	147.1	1	SNP	p	G120K	1	.	.	358	360	AAG	718	720	AAG	208;208;207	A,G;A,G;G,C	186,1;189,1;185,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2470	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1673	147.1	1	SNP	p	N121D	0	.	.	361	363	AAC	721	723	AAC	210;210;208	A;A,G;C	191;191,1;189	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2470	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1673	147.1	1	SNP	p	A121N	1	.	.	361	363	AAC	721	723	AAC	210;210;208	A;A,G;C	191;191,1;189	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	9128	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	4748	191.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	944	rpsJ	312	312	100.0	rpsJ.l6.c30.ctg.1	1046	89.7	1	SNP	p	V57M	1	.	.	169	171	ATG	528	530	ATG	191;192;189	A;T;G	181;183;178	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
